It’s an exciting time in the sequencing industry. After years of dominance, Illumina started facing competition on all fronts in 2022. Element Biosciences and Singular Genomics launched their desktop sequencers. The US market opened up for MGI (via the Complete Genomics brand that never quite went away). And Ultima Genomics announced the early access program...
Since 2022 saw an explosion of new competition in the sequencing market, I thought this would be a good time to review the market share breakdown for the various players. This should serve as a good reference point going forward to see what kind of impact all the new players will make. Rather than relying...
Here’s my take on what we might see in 2020 for the sequencing platform market. This isn’t specifically about JPM, but I wanted to get this out ahead of the conference since it’s obviously one of the main venues for “big announcements”. Illumina 1) Merger/long reads I was all prepared to...
Every so often someone will ask about the various “generations” of DNA sequencing or a company will claim to have the latest generation – 3rd, 4th, even “last”. (Hey, Genia, if you don’t come out with something soon, I’m going to start calling your platform “late” generation sequencing – as in “late to the party”...